Opinion
12dOpinion
Have your parents or grandparents ever had trouble driving, reading or recognizing faces? They might be suffering from age-related macular degeneration, a progressive disease afflicting about 11 ...
Let there be green light: The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which ...
Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB ...
BBC on MSN13d
How blind yoga is helping people with sight lossThe 60-minute classes, which are all done seated, include meditation, breathing techniques and mindfulness exercises ...
Live Science on MSN9d
LED device treats leading cause of vision loss with light therapy, FDA saysThe Food and Drug Administration will allow a new device to be marketed as a treatment for dry age-related macular ...
The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related ...
HuidaGene Therapeutics gets US FDA clearance for CRISPR/Cas13 RNA-editing HG202 for macular degeneration: Shanghai Tuesday, November 5, 2024, 09:00 Hrs [IST] HuidaGene Therapeutic ...
PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...
Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet ...
HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback